MASTER INVESTOR SHOW 2025
The UK's largest event for private investors
Business Design Centre, London, 29 March 2025
Day(s)
:
Hour(s)
:
Minute(s)
:
Second(s)
Juvenescence Therapeutics
Juvenescence Therapeutics (JuvRx) is the division within Juvenescence dedicated to developing novel medicines to treat age-related diseases, comprising our majority and wholly owned first-in-class medicines.
Our mission is to prolong the period of life spent in health (healthspan) with novel therapeutics that target the underlying causes of age-related disease. Our work is based on the novel scientific understanding of the underlying biological causes of ageing. We aim to get life-changing therapeutics to patients and enable people to improve their health in a preventative fashion. JuvRx is being led by an experienced technical team of drug developers who, combined, have made major contributions to drug peak sales of more than $30 billion, led by Richard Marshall who was awarded a CBE whilst at Astra Zeneca for his work on the covid vaccine.
We have a pipeline of therapies entering human studies in the next 12 months, including:
- First-in-class oral PAI-1 inhibitor for fibrotic lung/kidney disease – IND filing imminent with Phase 1 starting in Q1 2024
- GDF15 mAb on the path to a Phase 1 in Q3 2024 and follow on bispecific mAb (with Activin A) entering preclinical development
- First-in-class oral CD38 inhibitor for Rheumatoid Arthritis – on track for Phase 1 commencement in Q4 2024
Get your ticket
Don't miss out on the UK's largest event for private investors - secure your ticket today.
SUBSCRIBE